Phase Ib Dose Finding Study of Abiraterone Acetate Plus BEZ235 or BKM120 in Patients With Castration-resistant Prostate Cancer.

Trial Profile

Phase Ib Dose Finding Study of Abiraterone Acetate Plus BEZ235 or BKM120 in Patients With Castration-resistant Prostate Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Buparlisib (Primary) ; Dactolisib (Primary) ; Abiraterone acetate; Prednisone
  • Indications Prostate cancer
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Mar 2017 Results published in the European Journal of Cancer
    • 11 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top